Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines entered a multi-target collaboration and license agreement with Zealand Pharma to design multispecific protein therapeutics for obesity and metabolic diseases using Generate's generative AI platform. Generate will receive $30M upfront plus up to $35M in early preclinical milestones, and is eligible for up to nearly $1.2B in total milestones plus tiered royalties on worldwide net sales for two initial programs, with an option to add a third.
Key figures
- Deal Value Usd
- $1.2 billion (total potential milestones)
- Initial programs
- 2
- Optional program
- third program option
- Upfront payment usd
- 30000000
- Total potential milestones usd
- 1200000000
- Early preclinical milestones usd
- 35000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.